ReviewPathogens & immunity2024
Hypervirulent
Review in Pathogens & immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mortality risk of carbapenem-resistant hypervirulentFrontiers in public health · 2025Pooled it
- Article
- Clinical and genomic profiling ofVirulence · 2026Article
- Klebsiella genus as driver of human disease: from infections to non-communicable disorders.Nature reviews. Microbiology · 2026Review
- Genomic characterization of CTX-M-15-producing Klebsiella pneumoniae ST709-KL9 from neonatal bacteraemia in eastern India.Molecular biology reports · 2026Article
- Molecular characterization of carbapenem resistance and hypervirulence determinants of Klebsiella pneumoniae circulating in a tertiary hospital in Cyprus.Molecular biology reports · 2026Article
- A rapid molecular assay for the detection of hypervirulentMicrobiology spectrum · 2026Article
- Emerging hypervirulentInfectious medicine · 2026Review
- HypervirulentInternational journal of surgery case reports · 2026Article
- Associations of Biofilm Capacity with Antimicrobial Resistance and Virulence Genes inAntibiotics (Basel, Switzerland) · 2026Article
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
- Phosphorylation Modification Characteristics of Liver Injury-Related Proteins inPathogens (Basel, Switzerland) · 2026Article
- Molecular Epidemiological Analysis of Carbapenem-Resistant Hypervirulent Klebsiella Pneumoniae in Cangzhou Central Hospital from 2021 to 2024.Pakistan journal of medical sciences · 2026Article
- Interconnected Reservoirs: Virulence & Biofilm Traits of ESBL-Microorganisms · 2026Article
- Comparative profiling of virulence determinants, capsular serotypes, and antimicrobial resistance in hypervirulent and classical Klebsiella pneumoniae isolates from liver abscess patients.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Exploring the Antimicrobial Efficacy of Mesenchymal Stem Cell Secretome Against Klebsiella pneumoniae in Urinary Tract Infections.Clinical and translational science · 2026Article
- Genetic clusteringof KPC-2-producing carbapenem-resistant Klebsiella pneumoniae ST5422-KL19 in Shanghai, China.BMC microbiology · 2026Article
- Review
- Emergence and Genomic Characterization of a Hypervirulent Klebsiella pneumoniae Isolate From a New Clone in Brazil.Microbiology and immunology · 2026Article
- Comparative genomic analysis of hypervirulent and classical Klebsiella pneumoniae isolates from respiratory samples: A computational assessment of virulence genes.Functional & integrative genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.